Private‑sector testing leaders described analytical, sampling and stability problems for hemp products, including matrix effects, certificate‑of‑analysis misuse, decarboxylation uncertainties and the need for accredited labs.

CMS asked stakeholders to comment on whether pathology specimen retention periods should be extended, how specimen-prep personnel should be qualified, performance specifications for non-FDA-cleared tests, AI-assisted interpretation, and the effectiveness of remote competency assessments.

NMS Labs resolves measurement errors and updates procedures after testing method failures.

On June 18, 2026 the Nevada Cannabis Compliance Board adopted a comprehensive regulatory package (LCB file R152‑24‑RP1) addressing licensing, testing, packaging and lab accreditation after extended public comment and a contentious debate over laboratory standards and an increase in minimum sample size.

Legislation clarifies definitions of clinical laboratory scientists, specialists, and technicians in healthcare.

Experts voice concerns about lab inconsistencies impacting data quality for environmental trends.